Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

20260 citationsJournal Articlegold Open Access

Authors

Charles Shear · Biopharma Technology (United Kingdom)

Michael H. Davidson · Kiadis Pharma (Netherlands)

Marc Ditmarsch · Kiadis Pharma (Netherlands)

J J Kastelein · Kiadis Pharma (Netherlands)

MICHAEL SZAREK · SUNY Downstate Health Sciences University

Abstract

Within the limitations of the drugs studied and the variability in MACE definitions, there is value in the results of non-CVOTs to predict the CVOT outcome.

Topics & Keywords

Lipoproteins and Cardiovascular Health Antiplatelet Therapy and Cardiovascular Diseases Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Heart Journal Plus Cardiology Research and Practice

Volume 63, pp. 100728-100728

DOI: 10.1016/j.ahjo.2026.100728

Field-Weighted Citation Impact: 0.00